1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. October 7, 2025: Tobacco Products Scientific Advisory Committee Meeting - 10/07/2025
  1. Advisory Committee Calendar

Advisory Committee Meeting | Virtual

Event Title
October 7, 2025: Tobacco Products Scientific Advisory Committee Meeting
October 7, 2025

Date:
October 7, 2025
Time:
9:00 a.m. - 4:30 p.m. ET

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

Online Viewing

Agenda

On October 7, 2025, the Center for Tobacco Products’ TPSAC will meet virtually for an open session to discuss the renewal of modified risk granted orders issued to Philip Morris Products S.A. for the following products: 

  • Marlboro Amber HeatSticks  
  • Marlboro Green Menthol HeatSticks  
  • Marlboro Blue Menthol HeatSticks 
  • IQOS 2.4 System Holder and Charger 
  • IQOS 3.0 System Holder and Charger

Discussion will focus on whether the statutory standards continue to be met.  

Meeting Materials

FDA intends to make background material available to the public no later than two business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the time of the advisory committee meeting and be posted on the FDA’s website after the meeting. 

Public Participation Information

This will be a virtual-only meeting. Participants can attend via a live webcast.

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. 

  • Requests to make an oral presentation to be submitted to the contact person on or before September 11, 2025. 
  • Written submissions may be submitted to the contact person on or before September 25, 2025. 
  • Oral presentations from the public will be scheduled between 1:00 p.m. and 2:00 p.m. ET on October 7, 2025.

Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement describing the general nature of the evidence or arguments they wish to present, the names and email addresses of proposed participants on or before September 11, 2025. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.   

Contact Information

  • Rachel Jang, PharmD, DFO: 1-877-287-1373, TPSAC@fda.hhs.gov
  • FDA Advisory Committee Information Line: 1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the FDA's website and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rachel Jang, PharmD, DFO at least 7 days in advance of the meeting.

Review the Federal Register notice about this meeting for additional details.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Back to Top